Search results: (10000)
News Cannabidiol as a way to reduce anxiety in patients with Parkinson's disease?
A recent study by Brazilian authors examined the effects of cannabidiol on tremors and anxiety in patients with Parkinson's disease. Could it represent a promising modality in this indication?
News Sports in People with Hemophilia – Possible and Safe
Active involvement in sports and an active lifestyle are important aspects of daily functioning for people with hemophilia. Modern treatment of this disease, including the prophylactic administration of concentrates of the missing coagulation factor, has led to an increase in the number of very active patients. Numerous studies have confirmed that they are as physically active as the general population, although some emphasize that this is more relevant to children and young people. Therefore, the work of Dutch and Swedish authors focused on examining the relationship between age and physical activity in hemophiliacs, especially with regard to more intensive and riskier sports.
News Do Beta-Blockers Increase the Risk of Hypoglycemia in Patients with Diabetes and Atherosclerosis?
Given that a large portion of patients with diabetes have proven cardiovascular disease, several clinical studies or their subsequent analyses address the effects of beta-blockers in these patients. One such analysis was the post-hoc analysis of the TECOS study, which among other things, attempted to evaluate the connection between the use of beta-blockers in type 2 diabetics with proven atherosclerotic cardiovascular disease and the incidence of hypoglycemic episodes.
News Turoctocog Alfa in Tertiary Prophylaxis of Hemophilia A or Is It Always About Bleeding? Case Studies
This case report from our own practice concerns our experience with the treatment of hemophilia A with turoctocog alfa. The intention is, among other things, to compare different outcomes in our two patients regarding their self-assessment of bleeding without objective validation.
News Brief from ASH 2021: News and Advances in CLL Treatment
The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia (CLL). Dr. Brian Koffman from the CLL Society provided commentary on these developments.
News Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis
Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. At the 24th World Congress of Dermatology in Milan in June 2019, results were presented from a study evaluating the efficacy and safety of long-term administration of ixekizumab.
News Effectiveness of Dietary Intervention in Irritable Bowel Syndrome – Results of a Network Meta-Analysis
A low FODMAP diet is often recommended to alleviate symptoms of irritable bowel syndrome (IBS). Although several randomized studies have been conducted to assess the effectiveness of this diet, a systematic evaluation has yet to be available, and individual studies have used various control interventions. Therefore, an international team of researchers decided to prepare a systematic literature review with a network analysis, recently published in the journal Gut.
News Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice
In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary arterial hypertension in real-world practice were published from the international EXPERT registry, which also included Czech patients. The safety profile of the therapy was consistent with the findings of previous clinical studies.
News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab
In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.
News Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype
A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic marker in chronic lymphocytic leukemia (CLL). An analysis of the impact of complex karyotype on the efficacy of targeted CLL therapy combining the monoclonal antibody against CD20 antigen obinutuzumab with the BCL2 inhibitor venetoclax or the alkylating cytostatic chlorambucil was published in the journal Blood.
News Alzheimer's Disease – Another Pandemic on the Horizon?
Due to the COVID-19 pandemic, other current problems often get pushed into the background. One of these is the aging population and the increasing prevalence of dementia. The key question thus becomes how to extend the period of active aging as much as possible.
News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
News How to Secure Diabetics with Atrial Fibrillation During PCI?
Optimal management of patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) continues to be the subject of studies. A sub-analysis of the RE-DUAL study focused on this issue in a high-risk group of patients with diabetes.
News Physiotherapy as Part of Comprehensive Care for People with Hemophilia – Recommendations vs. Reality
It appears that the physiotherapeutic care provided in reality to people with hemophilia does not align with current recommendations, which see it as an integral part of a multidisciplinary approach. Therefore, in the summer of 2020, an initiative of experts from various countries, including the Czech Republic, was formed to address this issue.
News Undiagnosed Hereditary Angioedema in Pregnancy – Case Study
Delayed diagnosis or misdiagnosis is not uncommon with hereditary angioedema (HAE), especially during pregnancy and the postpartum period. A case study by Canadian authors illustrates that HAE should be considered in the differential diagnosis for any patient with unexplained abdominal pain and recurrent swellings without the presence of urticaria.
News Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.
News Fixed Combination of Tiotropium/Olodaterol in SMI Inhaler and Its Benefits in COPD Treatment
The TRONARTO study, whose conclusions were published in the International Journal of Chronic Obstructive Pulmonary Disease, addressed the issue of inhalation therapy in patients with chronic obstructive pulmonary disease (COPD). The authors focused on the effect of the combination of tiotropium and olodaterol in an SMI (soft mist inhaler) type inhaler.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Good news for sleep in patients with axial spondyloarthritis – ixekizumab effectively reduces night-time back pain
The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.
News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
News Third Generation Targeted Therapy for ROS1-Positive NSCLC
The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
News Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides a summary of a recent observational study that investigated the appropriate timing of starting dabigatran in patients with non-valvular atrial fibrillation (NVAF) after their first iCMP who were treated with intravenous thrombolysis or endovascular thrombectomy.